Drug Trial Radar · NCT00003569
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
Last checked: Nov 19, 2026Latest source record: Jan 31, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2
Actual
Start
Mar 1998
Primary completion
Jun 2003
Sponsor
- Lead sponsor
- Roswell Park Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 27, 2003
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from the side effects of chemotherapy. PURPOSE: This phase I trial is studying the side effects and best dose of dimesna in treating patients with solid tumors who are receiving cisplatin and paclitaxel.
Conditions
- Head and Neck Cancer
- Lung Cancer
- Neurotoxicity
- Ovarian Cancer
Interventions
cisplatinDrug
dimesnaDrug
paclitaxelDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Chicago Cancer Research Center
Chicago, Illinois
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Roswell Park Cancer Institute
Buffalo, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.